№ lp_2_1_32154
File format: docx
Character count: 36865
File size: 358 KB
This document presents a detailed analysis of the predicted versus actual use of teduglutide for treating Type III Short Bowel Syndrome with intestinal failure in Australia over a 24-month period since its PBS listing.
Year:
2022
Region / city:
Australia
Topic:
Pharmacology, Drug Utilisation
Document type:
Research analysis
Organization:
Drug utilisation sub-committee (DUSC)
Author:
Not specified
Target audience:
Healthcare professionals, medical researchers
Period of validity:
Not specified
Date of approval:
1 October 2019
Date of revisions:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2021
Region:
Australia
Topic:
Pharmacology / Drug utilisation
Document type:
Report
Organization:
Drug Utilisation Sub-Committee (DUSC), Department of Health, Services Australia
Drug:
Tolvaptan
Condition:
Autosomal dominant polycystic kidney disease (ADPKD)
Population:
Adults with chronic kidney disease stage 1–3
Data source:
Pharmaceutical Benefits Scheme (PBS) database
Date of PBS listing:
1 January 2019
Treatment criteria:
Nephrologist management, eGFR 30–89 mL/min/1.73m², evidence of rapidly progressing disease
Monitoring requirements:
Liver function tests prior to initiation, monthly for 18 months, then every 3 months
Dosage forms:
15 mg, 30 mg, 45 mg, 60 mg, 90 mg tablets in split-dose regimens
Analysis period:
First and second year of PBS listing
Year:
2026
Region / City:
Ternopil, Ukraine
Topic:
Environmental science, Toxicology, Biochemistry
Document type:
Research article
Institution:
Ternopil Volodymyr Hnatiuk National Pedagogical University, I. Horbachevsky Ternopil National Medical University, Nature Research Centre
Authors:
Vira Khoma, Viktoria Martinyuk, Tetyana Matskiv, Lesya Gnatyshyna, Vitaliy Baranovsky, Mykola Gladiuk, Brigita Gylytė, Levonas Manusadžianas, Oksana Stoliar
Target audience:
Researchers in environmental science, toxicology, biochemistry
Period of validity:
N/A
Approval date:
N/A
Date of changes:
N/A
Year:
2026
Institution:
Città della Salute e della Scienza of Turin, hospital
Document type:
Supplementary table
Subject:
Melanoma prognosis
Population:
Hypothetical patients
Variables:
Age, Breslow thickness, Ulceration, Regression, Histotype, Positive lymph nodes count, Tumour burden
Data type:
Cumulative incidence (CI)
Methodology:
Predicted probability calculations
Intended audience:
Medical researchers, clinicians
Year:
2025
Region / city:
Australia
Topic:
Severe asthma treatment and medication analysis
Document type:
Report
Organization:
Drug Utilisation Sub-committee (DUSC)
Author:
Unknown
Target audience:
Healthcare professionals, policymakers
Period of validity:
April 2025
Date of approval:
Not mentioned
Date of changes:
Not mentioned
Year:
2026
Institution:
University of Edinburgh, College of Medicine and Veterinary Medicine
Document Type:
Academic Form
Region / Country:
Canada
Target Audience:
Students completing Year 12 examinations
Required Information:
Applicant name, UCAS Personal ID, School details, Predicted grades, Teacher signature
Subjects Covered:
English and other Year 12 subjects
Submission Method:
Electronic completion preferred
Purpose:
Recording predicted academic grades for university application
Year:
2016
Region / city:
Australia
Topic:
Pharmaceutical utilisation / hepatic encephalopathy
Document type:
Analytical report
Organization / institution:
Drug Utilisation Sub-Committee (DUSC), Department of Human Services (DHS)
Author:
DUSC
Target audience:
Healthcare policymakers, clinicians
Period covered:
December 2013 – March 2016
Date of listing:
1 December 2013
Drug:
Rifaximin
Indication:
Prevention of hepatic encephalopathy recurrence
Dosage:
550 mg twice daily
Treatment requirements:
Combination with lactulose if tolerated; prior episodes of HE required
Regulatory authority:
Therapeutic Goods Administration (TGA)
PBS restriction:
Specialist treatment only; telephone authority approval required
Study type:
Retrospective utilisation analysis
Key findings:
Patient numbers higher than predicted; prescriptions per patient lower than estimated; expenditure aligned with second-year projections
Year:
2026
Region / city:
Not specified
Subject:
Neuropeptide sequences in Arma custos
Document type:
Scientific data
Institution:
Not specified
Author:
Not specified
Target audience:
Researchers in biochemistry, molecular biology, and neurobiology
Validity period:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Department:
U.S. Department of Housing and Urban Development
Office:
Office of Hospital Facilities
Program:
Section 242 Hospital Mortgage Insurance
Legal Authority:
Section 242 of the National Housing Act; 24 CFR Part 242; 24 C.F.R. 242.422
Form Type:
Borrower certification form
OMB Approval No.:
2502-0602
OMB Expiration Date:
4/30/2026
Addressee:
Federal Housing Commissioner
Related Form:
HUD-93305-OHF
Supporting Form:
HUD-92330A-OHF
Subject:
Certification of actual construction costs and disclosure of Identity of Interest
Project Information:
Project Number; Project Name; Location
Compliance Requirement:
Independent Certified Public Accountant certification if required by HUD regulations
Sanctions Notice:
Criminal, civil, and administrative penalties for false statements
Administering Agency:
U.S. Department of Housing and Urban Development
Year:
2026
Region / City:
United States
Subject:
Construction Cost Certification
Document Type:
Certificate
Agency / Organization:
U.S. Department of Housing and Urban Development (HUD)
Author:
Not specified
Target Audience:
Contractors, Borrowers, Federal Housing Commissioner
Effective Period:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
Not specified
State:
Michigan
Country:
United States
Subject:
Child abuse and neglect reporting
Document type:
Official reporting form
Issuing authority:
Michigan Department of Health and Human Services
Legal basis:
P.A. 238 of 1975
Completion requirement:
Mandatory
Penalty:
None
Related procedure:
Written follow-up to oral report under Sec. 3 (1) of 1975 PA 238, as amended
Recipient office:
Centralized Intake for Abuse & Neglect
Submission methods:
Mail, fax, email
Intended reporters:
Mandated reporters and other individuals reporting suspected child abuse or neglect
Medical section:
To be completed by medical personnel when physical examination has been done
Year:
2021
Region:
Australia
Topic:
Pharmacology / Drug utilisation
Document type:
Report
Organization:
Drug Utilisation Sub-Committee (DUSC), Department of Health, Services Australia
Drug:
Tolvaptan
Condition:
Autosomal dominant polycystic kidney disease (ADPKD)
Population:
Adults with chronic kidney disease stage 1–3
Data source:
Pharmaceutical Benefits Scheme (PBS) database
Date of PBS listing:
1 January 2019
Treatment criteria:
Nephrologist management, eGFR 30–89 mL/min/1.73m², evidence of rapidly progressing disease
Monitoring requirements:
Liver function tests prior to initiation, monthly for 18 months, then every 3 months
Dosage forms:
15 mg, 30 mg, 45 mg, 60 mg, 90 mg tablets in split-dose regimens
Analysis period:
First and second year of PBS listing
Year:
2024
Region / City:
Alameda County, City of Anaheim, Contra Costa County, Foothill, Fresno, Golden Sierra, Humboldt County, Imperial County, Employers Training Resource, Kings County, Los Angeles, Long Beach, Madera County, Merced County, Monterey County, Mother Lode, Northern Rural Training and Employment Consortium (NORTEC), North Central Counties Consortium, NOVA, City of Oakland, Orange County, Richmond
Subject:
Workforce Development
Document Type:
Report
Organization:
Workforce Development Boards
Target Audience:
Workforce Development Professionals
Period of Validity:
2024
Approval Date:
Not specified
Date of Amendments:
Not specified
Note:
Description
Note:
Year
Topic:
Exercise Motivation and Benefits
Document Type:
Questionnaire
Year:
2025
Region / City:
United States
Topic:
Criminal Law / DUI
Document Type:
Statute
Organization / Institution:
State Legislature
Author:
Not specified
Target Audience:
Public / Legal professionals
Effective Date:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Context:
A legal statute outlining penalties and procedures for operating a motorized watercraft under the influence of alcohol.
Year:
2021
Region / City:
Chongqing, Hong Kong
Topic:
Chemical dynamic modeling, Neural networks, Attention mechanisms
Document Type:
Research article
Institution:
Chongqing University, Chongqing Technology and Business University, The Hong Kong Polytechnic University
Authors:
Yue Li, Ning Li, Jingzheng Ren, Weifeng Shen
Target Audience:
Researchers in chemical engineering, machine learning, and neural networks
Period of Validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Context:
A research article on a neural network architecture (LACG) for modeling chemical dynamic processes with high accuracy.
Year:
2021-2022
Region / City:
Texas
Topic:
Public Education Financial Data
Document Type:
Report
Organization:
Texas Education Agency
Author:
Texas Education Agency
Target Audience:
School Districts, Charter Schools, Education Officials
Period of Action:
2021-2022
Approval Date:
Not specified
Modification Date:
April 11, 2023
Company:
AP Gas & Electric
Year:
2025
Reporting Period:
January 1, 2025 – June 30, 2025
Geographic Scope:
PJM Regional Wholesale Market
Document Type:
Environmental Disclosure Statement
Subject:
Electricity Generation Resource Mix and Environmental Characteristics
Energy Procurement:
Wholesale Market Purchases
Renewable Energy Certificates:
Covers 100% of Customer Electricity Usage
Generation Sources Listed:
Biomass, Coal, Hydro, Natural Gas, Nuclear, Oil, Solar, Wind, Other Sources, Unknown Purchased Resources
Environmental Indicators:
Air Emissions, Solid Waste, Wildlife Impacts, Radioactive Waste
Radioactive Waste Reporting Unit:
Lbs./1,000 kWh; Ft³/1,000 kWh
Contact Information:
www.apge.com
Note:
; 1-888-797-4537
Year:
2025
Region / City:
Madison, Wisconsin
Topic:
Event Reimbursement
Document Type:
Report
Organization:
JD Grants Committee
Author:
JD Grants Committee
Target Audience:
Event Organizers, Law School Personnel
Period of Validity:
2025-2026
Approval Date:
May 20, 2025
Revision Date:
N/A